{
    "clinical_study": {
        "@rank": "102710", 
        "arm_group": [
            {
                "arm_group_label": "FRM-0334; Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "low dose, Capsule, Once Daily, Day 1 through Day 28"
            }, 
            {
                "arm_group_label": "FRM-0334; Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "high dose, Capsule, Once Daily, Day 1 through Day 28"
            }, 
            {
                "arm_group_label": "Placebo Comparator; Arm 3", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, Capsule, Once Daily, Day 1 through Day 28"
            }
        ], 
        "brief_summary": {
            "textblock": "The purposes of this study are to investigate the safety, tolerability, and pharmacodynamics\n      of FRM-0334 in subjects with prodromal to moderate frontotemporal dementia with granulin\n      mutation."
        }, 
        "brief_title": "Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation", 
        "condition": "Granulin Mutation", 
        "condition_browse": {
            "mesh_term": [
                "Dementia", 
                "Frontotemporal Dementia", 
                "Aphasia, Primary Progressive", 
                "Pick Disease of the Brain"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female ages aged \u226521 and \u226475 years\n\n          -  Genotyped positive for a FTD-GRN mutation, and aware of it\n\n          -  Prodromal to moderate FTD-GRN\n\n          -  Resides in a stable living situation, living at home, senior residential setting, or\n             an institutional setting without the need for continuous (ie, 24-hour) nursing care\n\n          -  Proficiency (oral and written) in the language in which study-related documents,\n             including the ICF and  standardized tests, will be administered\n\n          -  Able to swallow capsules\n\n          -  Be in good general health, willing and able to comply with the protocol requirements,\n             and expected to complete the study as designed (in the judgment of the investigator)\n\n        Exclusion Criteria:\n\n          -  Clinically significant abnormalities on physical examination, medical history,  ECG,\n             vital signs, laboratory values, or unstable medical or psychiatric illness\n\n          -  Females who are pregnant, breastfeeding, or planning to become pregnant during the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149160", 
            "org_study_id": "FRM-0334-002", 
            "secondary_id": "2014-001489-85"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "FRM-0334; Arm 1", 
                    "FRM-0334; Arm 2"
                ], 
                "intervention_name": "FRM-0334", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Comparator; Arm 3", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Histone Deacetylase Inhibitors"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Histone deacetylase inhibitor", 
            "Frontotemporal dementia", 
            "Granulin"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Charlestown", 
                    "country": "United States", 
                    "state": "Massachusetts"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation", 
        "overall_contact": {
            "email": "ckeefe@forumpharma.com", 
            "last_name": "Carla Keefe", 
            "phone": "617-225-4289"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "France: Ministry of Health", 
                "Italy: Ministry of Health", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number and percentage of subjects with AEs\nNumber and percentage of subjects with SAEs\nNumber and percentage of subjects who discontinue due to AEs\nNumber and percentage of subject deaths", 
                "measure": "Evaluate the safety and tolerability of FRM-0334", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Day 28 or Early Termination"
            }, 
            {
                "measure": "Assess the pharmacodynamic (PD) effects of FRM-0334 on the change from baseline in plasma concentrations of progranulin (PGRN) after 28 days", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 28 or Early Termination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149160"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in CSF progranulin concentration from baseline", 
                "measure": "Assess the pharmacodynamic effects of FRM-0334 on the change from baseline in cerebrospinal fluid (CSF) concentrations of PGRN after 28 days", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 28"
            }, 
            {
                "description": "Cmax, Ctrough, tmax, t1/2, \u03bbz, AUC(0-\u03c4), CL/F, Cav in plasma", 
                "measure": "Characterize the plasma concentrations of FRM-0334 and metabolites following once daily dosing for 28 days", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 28 or Early Termination"
            }, 
            {
                "description": "Cmax, Ctrough, tmax, t1/2, AUC0-\u03c4, CL/F, Cav in CSF", 
                "measure": "Characterize the CSF concentrations of FRM-0334 and metabolites following once daily dosing for 28 days", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 28 or Early Termination"
            }
        ], 
        "source": "FORUM Pharmaceuticals Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "FORUM Pharmaceuticals Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}